Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?

American Journal of Nephrology

Volumn 47, Issue 2, 2018, Pages 72-83

  Wish, Jay B ^a   Aronoff, George R ^b,c   Bacon, Bruce R ^d   Brugnara, Carlo ^e   Eckardt, Kai Uwe ^f   Ganz, Tomas ^g   Macdougall, Iain C ^h   Núñez, Julio ⁱ   Perahia, Adam J ^j   Wood, John C ^k  

^a INDIANA UNIVERSITY HEALTH   (United States)

^b University of Louisville School of Medicine   (United States)

^c Davita Kidney Care   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h KING S COLLEGE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF VALENCIA   (Spain)

^j NorthStar Strategic Consulting   (United States)

^k CHILDREN S HOSPITAL LOS ANGELES   (United States)

more..

Author keywords

Chronic kidney disease; Hemodialysis; Hepcidin; Iron; Iron overload; Iron storage disorder; Transferrin

Indexed keywords

FERRITIN; IRON; TRACE ELEMENT;

ARTICLE; BIOAVAILABILITY; CHRONIC KIDNEY FAILURE; ERYTHROPOIESIS; HEMODIALYSIS; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; IRON ABSORPTION; IRON BALANCE; IRON BINDING CAPACITY; IRON DEFICIENCY ANEMIA; IRON HOMEOSTASIS; IRON INTAKE; IRON OVERLOAD; IRON STORAGE; IRON THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETICULOENDOTHELIAL SYSTEM; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM;

ADMINISTRATION, INTRAVENOUS; ERYTHROPOIESIS; HOMEOSTASIS; HUMANS; IRON; RENAL INSUFFICIENCY, CHRONIC; TRACE ELEMENTS;

EID: 85042083271     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000486968     Document Type: Article

References (82)

1. Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L: Mechanisms of mammalian iron homeostasis. Biochemistry 2012; 51: 5705-5724.
2. Muckenthaler MU, Lill R: Cellular iron physiology; in Iron Physiology and Pathophysiology in Humans. New York, Springer, 2012, pp 27-50.
3. Hentze MW, Muckenthaler MU, Andrews NC: Balancing acts: molecular control of mammalian iron metabolism. Cell 2004; 117: 285-297.
4. Macdougall IC, Bircher AJ, Eckardt KU, et al: Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) controversies conference. Kidney Int 2016; 89: 28-39.
5. Ganz T: Molecular control of iron transport. J Am Soc Nephrol 2007; 18: 394-400.
6. Rossi E: Hepcidin-the iron regulatory hormone. Clin Biochem Rev 2005; 26: 47-49.
7. Ganz T, Nemeth E: Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol 2016; 36: 87-93.
8. Sangkhae V, Nemeth E: Regulation of the iron homeostatic hormone hepcidin. Adv Nutr 2017; 8: 126-136.
9. Wood JC: Estimating tissue iron burden: current status and future prospects. Br J Haematol 2015; 170: 15-28.
10. Roberts MA, Huang L, Lee D, et al: Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial. BMC Nephrol 2016; 17: 177.
11. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T: Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014; 46: 678-684.
12. Srai SK, Sharp P: Proteins of iron homeostasis; in Iron Physiology and Pathophysiology in Humans. New York, Springer, 2012, pp 3-25.
13. Anderson ER, Shah YM: Iron homeostasis in the liver. Compr Physiol 2013; 3: 315-330.
14. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV: Serum ferritin: past, present and future. Biochim Biophys Acta 2010; 1800: 760-769.
15. Rosenblatt SG, Drake S, Fadem S, Welch R, Lifschitz MD: Gastrointestinal blood loss in patients with chronic renal failure. Am J Kidney Dis 1982; 1: 232-236.
16. Wizemann V, Buddensiek P, de Boor J, Grebe S, Schutterle G: Gastrointestinal blood loss in patients undergoing maintenance dialysis. Kidney Int Suppl 1983; 16:S218-S220.
17. Hocken AG, Marwah PK: Iatrogenic contribution to anaemia of chronic renal failure. Lancet 1971; 1: 164-165.
18. Sargent JA, Acchiardo SR: Iron requirements in hemodialysis. Blood Purif 2004; 22: 112-123.
19. Longnecker RE, Goffinet JA, Hendler ED: Blood loss during maintenance hemodialysis. Trans Am Soc Artif Intern Organs 1974; 20A:135-140.
20. Tsukamoto T, Matsubara T, Akashi Y, Kondo M, Yanagita M: Annual iron loss associated with hemodialysis. Am J Nephrol 2016; 43: 32-38.
21. Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR: Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis 2009; 16: 143-151.
22. Wish JB: What are the considerations in balancing benefits and risks in iron treatment?: the benefits of intravenous iron. Semin Dial 2017; 30: 20-22.
23. Handa P, Kowdley KV: A proton pump inhibitor a day keeps the iron away. Clin Gastroenterol Hepatol 2016; 14: 153-155.
24. Imai R, Higuchi T, Morimoto M, Koyamada R, Okada S: Iron deficiency anemia due to the long-term use of a proton pump inhibitor. Intern Med 2017, Epub ahead of print.
25. Zaritsky J, Young B, Wang HJ, et al: Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1051-1056.
26. Zaritsky J, Young B, Gales B, et al: Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010; 5: 1010-1014.
27. Zumbrennen-Bullough K, Babitt JL: The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 2014; 29: 263-273.
28. Fishbane S, Pollack S, Feldman HI, Joffe MM: Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 2009; 4: 57-61.
29. Stancu S, Stanciu A, Zugravu A, et al: Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis 2010; 55: 639-647.
30. Archer NM, Brugnara C: Diagnosis of irondeficient states. Crit Rev Clin Lab Sci 2015; 52: 256-272.
31. Wish JB: Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1(suppl 1):S4-S8.
32. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335.
33. Locatelli F, Barany P, Covic A, et al: Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant 2013; 28: 1346-1359.
34. Kliger AS, Foley RN, Goldfarb DS, et al: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 2013; 62: 849-859.
35. Moist LM, Troyanov S, White CT, et al: Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 2013; 62: 860-873.
36. Padhi S, Glen J, Pordes BA, Thomas ME: Management of anaemia in chronic kidney disease: summary of updated NICE guidance. BMJ 2015; 350:h2258.
37. Pollak VE, Lorch JA, Shukla R, Satwah S: The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9. 5 years of prospectively collected data. BMC Nephrol 2009; 10: 6.
38. US-DOPPS (Dialysis and Advanced CKD Outcomes and Practice Patterns Study Program) Practice Monitor. Serum ferritin (3 month average), continuous (ng/mL). December, 2016. http://www. dopps. org/DPM/ Files/meanferritinngml1-overallTAB. htm (accessed February 10, 2017).
39. Karaboyas A, Zee J, Morgenstern H, et al: Understanding the recent increase in ferritin levels in United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol 2015; 10: 1814-1821.
40. Bailie GR, Larkina M, Goodkin DA, et al: Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015; 87: 162-168.
41. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080.
42. Hatamizadeh P, Ravel V, Lukowsky LR, et al: Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant 2013; 28: 2889-2898.
43. Kuo KL, Hung SC, Lin YP, et al: Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS One 2012; 7:e50295.
44. Kuragano T, Matsumura O, Matsuda A, et al: Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 2014; 86: 845-854.
45. Feldman HI, Joffe M, Robinson B, et al: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632.
46. Miskulin DC, Tangri N, Bandeen-Roche K, et al: Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 2014; 9: 1930-1939.
47. Agarwal R, Kusek JW, Pappas MK: A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88: 905-914.
48. Macdougall IC, Bock AH, Carrera F, et al: FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-2084.
49. Roger SD, Gaillard CA, Bock AH, et al: Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FINDCKD trial. Nephrol Dial Transplant 2017; 32: 1530-1539.
50. Macdougall IC: Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions. Clin Kidney J 2017; 10(suppl 1):i16-i24.
51. Drueke TB, Massy ZA: Oral or intravenous iron for anemia correction in chronic kidney disease? Kidney Int 2015; 88: 673-675.
52. Gaweda AE, Ginzburg YZ, Chait Y, Germain MJ, Aronoff GR, Rachmilewitz E: Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant 2015; 30: 187-196.
53. Kapoian T, O'Mara NB, Singh AK, et al: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19: 372-379.
54. Coyne DW, Kapoian T, Suki W, et al: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study. J Am Soc Nephrol 2007; 18: 975-984.
55. Fishbane S: Balance of benefit and risk in intravenous iron treatment in chronic kidney disease. Semin Nephrol 2016; 36: 119-123.
56. Silvestre OM, Goncalves A, Nadruz W Jr, et al: Ferritin levels and risk of heart failure-the atherosclerosis risk in communities study. Eur J Heart Fail 2017; 19: 340-347.
57. Spina JC, del Rivero A, Kidd C, Pietrani M, Savulky L, Garcia Monaco RD: Noninvasive assessment of hepatic iron overload in patients with hemochromatosis. Rev Argent Radiol 2013; 77: 139-146.
58. Batts KP: Iron overload syndromes and the liver. Mod Pathol 2007; 20(suppl 1):S31-S39.
59. Milic S, Mikolasevic I, Orlic L, et al: The role of iron and iron overload in chronic liver disease. Med Sci Monit 2016; 22: 2144-2151.
60. Pandey R, Daloul R, Coyne DW: Iron treatment strategies in dialysis-dependent CKD. Semin Nephrol 2016; 36: 105-111.
61. Wick G: A field guide to iron needs in the patient on hemodialysis. Nephrol Nurs J 2009; 36: 389-392, 396-403.
62. Macdougall IC, Geisser P: Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis 2013; 7: 9-22.
63. Deira J, Gonzalez-Sanchidrian S, Polanco S, et al: Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients. Ren Fail 2016; 38: 1076-1081.
64. Tolouian R, Mulla ZD, Diaz J, Aguila J, Ramos-Duran L: Liver and cardiac iron deposition in patients on maintenance hemodialysis by magnetic resonance imaging T2. Iran J Kidney Dis 2016; 10: 68-74.
65. Holman R, Olynyk JK, Kulkarni H, Ferrari P: Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. Nephrology (Carlton) 2017; 22: 114-117.
66. Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al: Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012; 89: 87-93.
67. Turkmen E, Yildirim T, Yilmaz R, et al: HFE gene mutation is a risk factor for tissue iron accumulation in hemodialysis patients. Hemodial Int 2017; 21: 359-366.
68. Woorwood, M: Estimation of body iron stores; in Anderson GM, McLaren GD (eds): Iron Physiology and Pathophysiology in Humans. New York, Springer, 2012, pp 499-528.
69. Ferrari P, Kulkarni H, Dheda S, et al: Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 77-83.
70. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149.
71. Slotki I: Intravenous iron supplementation in the anaemia of renal and cardiac failure-a double-edged sword? Nephrol Dial Transplant 2005; 20(suppl 7):vii16-vii23.
72. Besarab A, Amin N, Ahsan M, et al: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538.
73. Mainous AG 3rd, Gill JM, Carek PJ: Elevated serum transferrin saturation and mortality. Ann Fam Med 2004; 2: 133-138.
74. Porter JB, Hershko C: Clinical use of iron chelators; in Anderson GM, McLaren GD (eds): Iron Physiology and Pathophysiology in Humans. New York, Springer, 2012, pp 591-627.
75. Wood JC: Use of magnetic resonance imaging to monitor iron overload. Hematol Oncol Clin North Am 2014; 28: 747-764.
76. Brissot P, Ropert M, Le Lan C, Loreal O: Nontransferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 2012; 1820: 403-410.
77. Le Lan C, Loreal O, Cohen T, et al: Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005; 105: 4527-4531.
78. Esposito BP, Breuer W, Slotki I, Cabantchik ZI: Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002; 32(suppl 1):42-49.
79. Ali M, Fayemi AO, Rigolosi R, Frascino J, Marsden T, Malcolm D: Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases. JAMA 1980; 244: 343-345.
80. EU Clinical Trials Register. https://www. clini c a l t r i a l s r e g i s t e r. e u / c t r-s e a r c h / t r i-al/2013-002267-25/GB (accessed February 11, 2017).
81. Koury MJ, Haase VH: Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol 2015; 11: 394-410.
82. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group: KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017; 7: 1-59.